Free Trial
NASDAQ:ATNF

180 Life Sciences 5/15/2024 Earnings Report

180 Life Sciences logo
$1.09 0.00 (0.00%)
As of 02:58 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

180 Life Sciences EPS Results

Actual EPS
-$1.68
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

180 Life Sciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

180 Life Sciences Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

180 Life Sciences' next earnings date is estimated for Monday, August 11, 2025, based on past reporting schedules.

Conference Call Resources

180 Life Sciences Earnings Headlines

As Bitcoin supply vanishes, this Trump-aligned token could explode
Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, the REAL opportunity lies with one specific altcoin that's perfectly positioned to capture the lion's share of capital…
See More 180 Life Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 180 Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 180 Life Sciences and other key companies, straight to your email.

About 180 Life Sciences

180 Life Sciences (NASDAQ:ATNF), a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

View 180 Life Sciences Profile

More Earnings Resources from MarketBeat